Cargando…
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway
Bcl-2 inhibitors display an effective activity in acute myeloid leukemia (AML), but its clinical efficacy as a monotherapy was limited in part owing to failure to target other antiapoptotic Bcl-2 family proteins, such as Mcl-1. In this context, the combination strategy may be a promising approach to...
Autores principales: | Shi, Yuan-Fei, Liu, Long, He, Ling-Li, Ye, Jing, Lin, Zhi-Juan, Yuan, De-Lin, Deng, Man-Man, Fang, Zhi-Hong, Carter, Bing Z., Xu, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376040/ https://www.ncbi.nlm.nih.gov/pubmed/32699295 http://dx.doi.org/10.1038/s41419-020-02762-w |
Ejemplares similares
-
Targeting MCL-1/BCL-X(L) Forestalls the Acquisition of Resistance to ABT-199
in Acute Myeloid Leukemia
por: Lin, Kevin H., et al.
Publicado: (2016) -
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020) -
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
por: Ko, Tun Kiat, et al.
Publicado: (2014) -
Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
por: Zhao, Jianyun, et al.
Publicado: (2016) -
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)